Arthur D Levinson Net Worth and Compensation
Arthur D Levinson holds a substantial net worth built from decades in biotech and tech leadership. His compensation includes base salary, equity awards, and director fees from Apple and other public companies. Forbes estimates his wealth based on holdings in Apple stock, Genentech legacy positions, and private investments.
Apple director compensation reports show annual equity grants and cash retainers for board members like Levinson. His net worth fluctuates with Apple share price, Genentech stock performance, and private asset valuations. Public filings and Forbes profiles provide updated figures on his total reported wealth and annual pay.
Arthur D Levinson Career Path and Leadership Roles
Arthur D Levinson served as CEO of Genentech, a leading biotechnology company, before transitioning to chairman roles. He guided Genentech through major drug development milestones and mergers while maintaining a focus on research and regulatory approvals.
He joined Apple's board of directors in 2000 and later became chairman, overseeing governance and executive compensation. His career bridges biotech innovation and tech governance, with board seats at multiple public and private companies.
Arthur D Levinson Board Roles and Governance Influence
Apple Board Chairman and Director Responsibilities
As Apple board chairman, Arthur D Levinson leads board meetings, nominates directors, and shapes governance policy. Apple proxy statements detail his committee assignments, equity holdings, and voting record on executive pay and acquisitions.
Apple's board governance framework relies on independent directors, and Levinson's role includes oversight of CEO succession and risk management. SEC filings and Apple investor relations pages provide his latest board compensation and stock ownership data.
Genentech Legacy and Biotech Board Influence
Arthur D Levinson's tenure at Genentech established a model for scientific leadership in boardrooms. He later served on multiple biotech and pharmaceutical boards, applying drug development expertise to corporate governance.